Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer

Documenti analoghi

• The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens
  di: Baralee Punyawudho, et al.
  Pubblicazione: (2024)
• Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib
  di: Tamara van Donge, et al.
  Pubblicazione: (2025)
• Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation
  di: Chiara Zunino, et al.
  Pubblicazione: (2025)
• Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration
  di: Peter Chang, et al.
  Pubblicazione: (2024)
• Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
  di: Anyue Yin, et al.
  Pubblicazione: (2024)